Drug Trial Radar · NCT07711262
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis. Eligible participants will be randomized to Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets (active comparator), or matching placebo. All treatments are administered once daily at a consistent time with a 24 ± 2-hour interval between doses for 2 consecutive weeks.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Rupatifen Fumarate CapsulesDrug
Oral administration, one capsule once daily for 14 consecutive days
Rupatadine Fumarate TabletsDrug
Oral administration, one tablet once daily for 14 consecutive days
Rupatifen Fumarate Capsules PlaceboDrug
Oral administration, one capsule once daily for 14 consecutive days
Rupatadine Fumarate Tablets PlaceboDrug
Oral administration, one tablet once daily for 14 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the average reflective Total Nasal Symptom Score (rTNSS) during the treatment periodTime frame: From baseline (Day 1 pre-dose) through Day 15 (end of treatment)
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, China · Recruiting
Emergency General Hospital
Beijing, China · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
Tianjin People's Hospital
Tianjin, China · Recruiting
The No.2 Hospital of Baoding
Baoding, Hebei, China · Recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, China · Recruiting
Hebei General Hospital
Shijiazhuang, Hebei, China · Recruiting
Hebei Provincial Hospital of Traditional Chinese Medicine
Shijiazhuang, Hebei, China · Recruiting
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China · Recruiting
Baogang Hospital of Inner Mongolia
Baotou, Inner Mongolia, China · Recruiting
Baotou Central Hospital
Baotou, Inner Mongolia, China · Recruiting
Chifeng Municipal Hospital
Chifeng, Inner Mongolia, China · Recruiting
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, China · Recruiting
Shandong Second Provincial General Hospital
Jinan, Shandong, China · Recruiting
Linfen Central Hospital
Linfen, Shanxi, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Second hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.